By presidential order, marijuana has been rescheduled from Schedule I to Schedule III. This is not a subtle bureaucratic shift. It is a historic decision with major medical, regulatory, and cultural implications. Yet, astonishingly, much of the medical community has responded with near silence. There has been little serious discussion, no broad professional debate, and minimal effort to educate clinicians or the public about what this change does, and does not, mean.

Rescheduling marijuana is often misunderstood as a declaration that cannabis is “safe” or that it belongs in a less toxic category. That is not what this decision represents. Schedule III status acknowledges that certain chemical components of the marijuana plant may have potential medicinal uses, even though adequate, high-quality evidence remains limited. It does not validate widespread recreational use, nor does it negate the growing body of literature documenting significant medical and psychiatric risks.

The potency problem

Today’s marijuana is not the marijuana of the 1970s. The products currently available, particularly high-THC strains, concentrates, and edibles, are far more potent and pharmacologically active than earlier recreational forms. This matters clinically.

Over the past two decades, research has increasingly linked marijuana use to the unmasking of schizophrenia and other psychotic disorders, especially in vulnerable individuals. Associations with cardiovascular events, impaired concentration and memory, mood instability, anxiety syndromes, and motor coordination problems are now well documented. These are not fringe concerns; they appear regularly in emergency rooms, psychiatric practices, and primary care settings.

The silence of medicine

Despite this, many medical organizations and clinicians have been conspicuously quiet. In contrast to the vigorous, and often well-funded, clamor from advocacy groups and commercial interests, medicine has largely failed to articulate a balanced, evidence-based position. This silence risks being interpreted by the public as tacit approval or indifference.

The reasons for this failure are multiple:

• Inadequate education: Medical education on cannabis remains strikingly inadequate, leaving physicians uncomfortable or uninformed.
• Blurred lines: Some clinicians participate, often perfunctorily, in “medical marijuana” certification clinics that blur the line between medical judgment and consumer access.
• Personal bias: Personal biases, whether libertarian, cultural, or generational, shape attitudes more than data.
• Minimization of risk: Perhaps most concerning is a broader trend within medicine: the tendency to minimize or dismiss addiction, misuse, and the long-term effects of psychoactive substances unless they fit familiar frameworks such as opioids or alcohol.

Defining the narrative

Rescheduling marijuana should have been a moment for serious professional engagement. Instead, it has passed with little scrutiny. As physicians, we have an obligation to look beyond political symbolism and commercial enthusiasm. Recognizing potential medicinal properties does not absolve us from acknowledging risks, setting boundaries, and demanding rigorous evidence.

If the medical community remains silent, others will define the narrative. And that narrative may bear little resemblance to clinical reality.

Farid Sabet-Sharghi is a psychiatrist.